Phase II multi-center, non randomized open label study of Ipilimumab (anti CTLA-4) administered as first line monotherapy in adults patients with metastatic uveal melanoma [Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico]

Trial Profile

Phase II multi-center, non randomized open label study of Ipilimumab (anti CTLA-4) administered as first line monotherapy in adults patients with metastatic uveal melanoma [Ensayo clínico fase II, no randomizado, para evaluar el papel de Ipilimumab en monoterapia, administrado en primera línea en pacientes afectos de melanoma uveal metastásico]

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2014

At a glance

  • Drugs Ipilimumab (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms MelUv1
  • Most Recent Events

    • 17 Oct 2011 Planned number of patients changed to 32.
    • 17 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top